Navigation Links
Harwood Feffer LLP Announces Investigation of Spectrum Pharmaceuticals, Inc.
Date:3/19/2013

NEW YORK, March 19, 2013 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ: SPPI), concerning whether the board has breached its fiduciary duties to shareholders.

(Logo:  http://photos.prnewswire.com/prnh/20120215/MM54604LOGO )

On March 12, 2013, the Company announced that sales of its drug, FUSILEV, would be significantly lower during 2013 due to changes in market demand for FUSILEV.  As a result, the Company decreased its 2013 revenue guidance from approximately $300 million to as low as $160 million.On this news, Spectrum shares lost more than 35% of their value in one day of trading to close at $7.79 per share on March 13, 2013, down from $12.43 per share at close on March 12, 2013.

Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.

If you own Spectrum shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:Robert I. Harwood, Esq.Matthew M. Houston, Esq.Benjamin I. Sachs-Michaels, Esq.Harwood Feffer LLP488 Madison AvenueNew York, New York 10022Phone Numbers:

(877) 935-7400(212)935-7400Email:  bsachsmichaels@hfesq.comWebsite:
http://www.hfesq.com Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. © 2013 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

 


'/>"/>
SOURCE Harwood Feffer LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Harwood Feffer LLP Announces Investigation of MAP Pharmaceuticals, Inc.
2. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
3. Harwood Feffer LLP Announces Investigation of PSS World Medical, Inc.
4. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
5. EGEN, Inc. Announces a Phase I Clinical Trial for Advanced Ovarian Cancer
6. National Minority Quality Forum Announces Support for Government Noninterference in Drug Price Negotiations
7. MGC Diagnostics Corporation Announces Worldwide Exclusive Distribution Partnership with Restech Respiratory Technology
8. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
9. BioElectronics Announces Chronic and Postoperative Wound Care Product Distribution in Italy
10. Athena Diagnostics Announces New Genetic Testing Services for Rare Neurological Disorders
11. Precision Optics Corporation Announces Reciept Of $660,000 Purchase Order For Custom-Designed Endoscopes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):